Cargando…

Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications

ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans-∆(9)-tetrahydrocannabinol (∆(9)-THC), the main psychoactive compound of cannabis. Synthesised in 2009 as a pharmaceutical drug candidate, the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobato-Freitas, Carolina, Brito-da-Costa, Andreia Machado, Dinis-Oliveira, Ricardo Jorge, Carmo, Helena, Carvalho, Félix, Silva, João Pedro, Dias-da-Silva, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996508/
https://www.ncbi.nlm.nih.gov/pubmed/33669071
http://dx.doi.org/10.3390/ph14030186
_version_ 1783670118390169600
author Lobato-Freitas, Carolina
Brito-da-Costa, Andreia Machado
Dinis-Oliveira, Ricardo Jorge
Carmo, Helena
Carvalho, Félix
Silva, João Pedro
Dias-da-Silva, Diana
author_facet Lobato-Freitas, Carolina
Brito-da-Costa, Andreia Machado
Dinis-Oliveira, Ricardo Jorge
Carmo, Helena
Carvalho, Félix
Silva, João Pedro
Dias-da-Silva, Diana
author_sort Lobato-Freitas, Carolina
collection PubMed
description ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans-∆(9)-tetrahydrocannabinol (∆(9)-THC), the main psychoactive compound of cannabis. Synthesised in 2009 as a pharmaceutical drug candidate, the recreational use of ADB-FUBINACA was first reported in 2013 in Japan, with fatal cases being described in 2015. ADB-FUBINACA is one of the most apprehended and consumed synthetic cannabinoid (SC), following AMB-FUBINACA, which emerged in 2014 as a drug of abuse and has since been responsible for several intoxication and death outbreaks. Here, we critically review the physicochemical properties, detection methods, prevalence, biological effects, pharmacodynamics and pharmacokinetics of both drugs. When smoked, these SCs produce almost immediate effects (about 10 to 15 s after use) that last up to 60 min. They are rapidly and extensively metabolised, being the O-demethylated metabolite of AMB-FUBINACA, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoic acid, the main excreted in urine, while for ADB-FUBINACA the main biomarkers are the hydroxdimethylpropyl ADB-FUBINACA, hydroxydehydrodimethylpropyl ADB-FUBINACA and hydroxylindazole ADB-FUBINACA. ADB-FUBINACA and AMB-FUBINACA display full agonism of the CB1 receptor, this being responsible for their cardiovascular and neurological effects (e.g., altered perception, agitation, anxiety, paranoia, hallucinations, loss of consciousness and memory, chest pain, hypertension, tachycardia, seizures). This review highlights the urgent requirement for additional studies on the toxicokinetic properties of AMB-FUBINACA and ADB-FUBINACA, as this is imperative to improve the methods for detecting and quantifying these drugs and to determine the best exposure markers in the various biological matrices. Furthermore, it stresses the need for clinicians and pathologists involved in the management of these intoxications to describe their findings in the scientific literature, thus assisting in the risk assessment and treatment of the harmful effects of these drugs in future medical and forensic investigations.
format Online
Article
Text
id pubmed-7996508
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79965082021-03-27 Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications Lobato-Freitas, Carolina Brito-da-Costa, Andreia Machado Dinis-Oliveira, Ricardo Jorge Carmo, Helena Carvalho, Félix Silva, João Pedro Dias-da-Silva, Diana Pharmaceuticals (Basel) Review ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans-∆(9)-tetrahydrocannabinol (∆(9)-THC), the main psychoactive compound of cannabis. Synthesised in 2009 as a pharmaceutical drug candidate, the recreational use of ADB-FUBINACA was first reported in 2013 in Japan, with fatal cases being described in 2015. ADB-FUBINACA is one of the most apprehended and consumed synthetic cannabinoid (SC), following AMB-FUBINACA, which emerged in 2014 as a drug of abuse and has since been responsible for several intoxication and death outbreaks. Here, we critically review the physicochemical properties, detection methods, prevalence, biological effects, pharmacodynamics and pharmacokinetics of both drugs. When smoked, these SCs produce almost immediate effects (about 10 to 15 s after use) that last up to 60 min. They are rapidly and extensively metabolised, being the O-demethylated metabolite of AMB-FUBINACA, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoic acid, the main excreted in urine, while for ADB-FUBINACA the main biomarkers are the hydroxdimethylpropyl ADB-FUBINACA, hydroxydehydrodimethylpropyl ADB-FUBINACA and hydroxylindazole ADB-FUBINACA. ADB-FUBINACA and AMB-FUBINACA display full agonism of the CB1 receptor, this being responsible for their cardiovascular and neurological effects (e.g., altered perception, agitation, anxiety, paranoia, hallucinations, loss of consciousness and memory, chest pain, hypertension, tachycardia, seizures). This review highlights the urgent requirement for additional studies on the toxicokinetic properties of AMB-FUBINACA and ADB-FUBINACA, as this is imperative to improve the methods for detecting and quantifying these drugs and to determine the best exposure markers in the various biological matrices. Furthermore, it stresses the need for clinicians and pathologists involved in the management of these intoxications to describe their findings in the scientific literature, thus assisting in the risk assessment and treatment of the harmful effects of these drugs in future medical and forensic investigations. MDPI 2021-02-25 /pmc/articles/PMC7996508/ /pubmed/33669071 http://dx.doi.org/10.3390/ph14030186 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Lobato-Freitas, Carolina
Brito-da-Costa, Andreia Machado
Dinis-Oliveira, Ricardo Jorge
Carmo, Helena
Carvalho, Félix
Silva, João Pedro
Dias-da-Silva, Diana
Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title_full Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title_fullStr Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title_full_unstemmed Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title_short Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications
title_sort overview of synthetic cannabinoids adb-fubinaca and amb-fubinaca: clinical, analytical, and forensic implications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996508/
https://www.ncbi.nlm.nih.gov/pubmed/33669071
http://dx.doi.org/10.3390/ph14030186
work_keys_str_mv AT lobatofreitascarolina overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT britodacostaandreiamachado overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT dinisoliveiraricardojorge overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT carmohelena overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT carvalhofelix overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT silvajoaopedro overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications
AT diasdasilvadiana overviewofsyntheticcannabinoidsadbfubinacaandambfubinacaclinicalanalyticalandforensicimplications